The Oncomine Chronic Myelomonocytic Leukemia (CMML) Panel Test is a cutting-edge diagnostic tool designed to provide comprehensive genetic insights into chronic myelomonocytic leukemia, a rare type of cancer that affects the blood cells and bone marrow. This test is conducted at DNA Labs UAE, a leading facility in genetic and genomic testing. Priced at 8190 AED, the test utilizes next-generation sequencing technology to analyze specific gene mutations associated with CMML, enabling healthcare professionals to tailor treatment strategies to the individual patient's genetic profile. By identifying mutations in genes that are pivotal in the development and progression of CMML, the Oncomine CMML Panel Test aids in the diagnosis, prognosis, and monitoring of the disease, offering a personalized approach to patient care.
The Oncomine Juvenile Myelomonocytic Leukemia (JMML) Panel Test is a specialized diagnostic tool designed to provide comprehensive genomic insights into Juvenile Myelomonocytic Leukemia, a rare and aggressive form of leukemia typically affecting children under the age of four. Conducted at DNA Labs UAE, this test employs next-generation sequencing technology to analyze a specific set of genes known to be associated with JMML. By examining these genetic markers, the test aims to identify mutations and alterations that can influence treatment decisions and prognosis.
Priced at 8190 AED, the Oncomine JMML Panel Test is a valuable resource for healthcare professionals, offering a deeper understanding of the genetic underpinnings of the disease. This information is crucial for tailoring treatment strategies to the individual patient, potentially improving outcomes. The test is conducted in the state-of-the-art facilities of DNA Labs UAE, ensuring high-quality and reliable results.
The Oncomine Myelodysplastic Syndrome (MDS) Panel Test is a cutting-edge diagnostic tool designed to provide comprehensive genetic insights into myelodysplastic syndromes, a group of bone marrow disorders characterized by the bone marrow's inability to produce enough healthy blood cells. Conducted at DNA Labs UAE, this test utilizes next-generation sequencing technology to analyze multiple genes simultaneously, enabling the identification of specific genetic mutations associated with MDS. This information is crucial for the precise diagnosis, prognosis, and tailoring of treatment plans for individuals with MDS.
The test is priced at 8190 AED, reflecting the advanced technology and expertise required to perform this sophisticated analysis. By pinpointing specific genetic abnormalities, the Oncomine MDS Panel Test helps healthcare professionals make more informed decisions regarding patient care, potentially leading to improved treatment outcomes. DNA Labs UAE, known for its commitment to quality and accuracy, ensures that this test is conducted under stringent quality controls, providing reliable and timely results for patients and their families.
The Oncomine Myeloproliferative Neoplasm (MPN) Panel Test is a sophisticated genetic testing tool designed to aid in the diagnosis and management of myeloproliferative neoplasms. Conducted at DNA Labs UAE, this test utilizes next-generation sequencing technology to analyze multiple genes simultaneously, which are known to be associated with MPNs. These disorders are a group of blood cancers characterized by the overproduction of blood cells in the bone marrow, and they include conditions such as polycythemia vera, essential thrombocythemia, and myelofibrosis.
By examining specific genetic mutations, the Oncomine MPN Panel Test provides critical information that can help in determining the specific type of MPN, prognostic implications, and potential therapeutic options. This personalized approach to diagnosis and treatment planning is at the forefront of precision medicine, offering patients a tailored strategy to manage their condition effectively.
The test is priced at 8190 AED, reflecting the comprehensive analysis and the sophisticated technology involved. Conducted in the state-of-the-art facilities of DNA Labs UAE, patients can expect high standards of accuracy and reliability in their test results, contributing to better-informed decisions regarding their health care.
The "Oncopro Focus Fusion Panel for Solid Tumors Test" is an advanced diagnostic tool designed to provide comprehensive genetic insights into solid tumors. This test, conducted at DNA Labs UAE, is aimed at identifying specific gene fusions and alterations that are critical in the development, progression, and treatment response of various solid tumors. With a cost of 8190 AED, the test utilizes cutting-edge sequencing technologies to analyze a panel of genes associated with solid tumors, offering precise and personalized information that can guide targeted therapy decisions. By pinpointing the genetic underpinnings of a patient's tumor, the Oncopro Focus Fusion Panel enables healthcare providers to tailor treatment strategies more effectively, potentially improving patient outcomes. This test represents a significant step forward in the field of oncology, offering hope for more effective and individualized cancer care.
Autoimmune Encephalitis Panel Serum and CSF Test is a comprehensive diagnostic assessment aimed at detecting autoimmune disorders that affect the brain, leading to encephalitis. This condition is characterized by inflammation of the brain, which can result in a wide range of neurological symptoms such as cognitive impairment, seizures, and psychiatric manifestations. The test involves analyzing both serum (blood) and cerebrospinal fluid (CSF) samples to identify specific antibodies that target the central nervous system, indicating an autoimmune response.
The Autoimmune Encephalitis Panel is crucial for the accurate diagnosis and timely management of autoimmune encephalitis, facilitating the differentiation from other types of encephalitis and guiding appropriate treatment strategies. Conducted at DNA Labs UAE, a leading diagnostic facility known for its advanced testing capabilities and expertise in genetic and autoimmune disorders, this test ensures high precision and reliability.
The cost of the Autoimmune Encephalitis Panel Serum and CSF Test at DNA Labs UAE is set at 8190 AED. While the price might seem substantial, the comprehensive insights provided by this test are invaluable for patients experiencing symptoms of autoimmune encephalitis, offering a clear path towards effective treatment and management of the condition.
The HLA DSA-SAB Class I IgG Antibodies with C1q Screen Test is a specialized diagnostic procedure designed to identify specific antibodies in the human body that can play a crucial role in organ transplant compatibility and rejection. HLA stands for Human Leukocyte Antigen, a marker found on most cells in the body, which the immune system uses to recognize which cells belong in the body and which do not. DSA refers to Donor-Specific Antibodies, which are antibodies that develop against the antigens of the donor organ. The presence of these antibodies can lead to transplant rejection.
This test specifically targets Class I IgG antibodies, which are a type of antibody involved in the immune response, along with a C1q screen. The C1q component is part of the complement system, which helps antibodies clear pathogens from an organism. The C1q screen is used to determine if the detected antibodies are likely to activate the complement system, which can lead to a higher risk of organ rejection.
The test is available at DNA Labs UAE, a leading facility for genetic and specialized tests. The cost of the HLA DSA-SAB Class I IgG Antibodies with C1q Screen Test is 7960 AED. This test is particularly important for patients undergoing organ transplantation, as it helps in assessing the risk of transplant rejection and in managing post-transplant care to improve the chances of success and longevity of the transplant.
The Beta-2-Transferrin Fluid Test is a specialized diagnostic tool used primarily to detect the presence of cerebrospinal fluid (CSF) leaks. This test is particularly useful in cases where a CSF leak is suspected due to trauma, surgical procedures, or certain medical conditions affecting the skull or spine. Beta-2-Transferrin is a protein that is almost exclusively found in cerebrospinal fluid, making it a highly specific marker for identifying CSF leaks when detected in other bodily fluids such as nasal discharge.
The test is conducted by collecting a sample of the fluid suspected to contain CSF, which is then analyzed in a laboratory setting. The presence of Beta-2-Transferrin in the sample confirms the leakage of cerebrospinal fluid.
In the United Arab Emirates, this test is available at DNA Labs UAE, a reputable laboratory known for its advanced diagnostic services. The cost of the Beta-2-Transferrin Fluid Test at DNA Labs UAE is 7,720 AED. This price reflects the sophisticated nature of the test and the specialized expertise required to accurately detect and analyze the Beta-2-Transferrin protein. Patients seeking this test at DNA Labs UAE can expect high-quality service and reliable results, which are crucial for the appropriate management and treatment of conditions associated with CSF leaks.
The HLA DSA-SAB Class II IgG Antibodies with C1q Screen Test is a specialized diagnostic procedure aimed at identifying specific antibodies that can have a critical impact on organ transplant compatibility and success. HLA (Human Leukocyte Antigen) antibodies are part of the immune system's response to perceived foreign entities. The presence of these antibodies can indicate a potential for organ rejection in transplant scenarios.
This test specifically targets the Class II IgG antibodies. These antibodies are directed against the donor's HLA antigens, which can lead to complications in transplant recipients if not identified and managed properly. The inclusion of the C1q screen adds an additional layer of specificity by identifying antibodies capable of activating the complement system, which is a part of the immune system that enhances the ability of antibodies and phagocytic cells to clear pathogens from an organism. The activation of the complement system by these antibodies can lead to a higher risk of graft damage or loss.
Performed at DNA Labs UAE, a facility known for its advanced diagnostic technologies and expert staff, the test is priced at 7380 AED. Given the complexity and the specialized nature of the test, it represents a critical investment in the pre-transplant assessment process, helping to ensure that potential recipients have the highest chance of a successful transplant outcome by identifying and addressing immunological risks before they can impact the graft.
The AAAS Full Gene Sequence Analysis Allogrove Syndrome Test is a comprehensive diagnostic tool offered by DNA Labs UAE, designed to detect Alagille Syndrome, a genetic disorder that can affect the liver, heart, and other parts of the body. This test specifically targets the AAAS gene, mutations in which are known to be a significant cause of this condition. By sequencing the entire gene, the test can identify both known and novel mutations, providing crucial information for accurate diagnosis and management of the syndrome.
Priced at 7250 AED, the test is conducted in the state-of-the-art facilities of DNA Labs UAE, ensuring high-quality standards and reliable results. This test is particularly important for individuals with a family history of Alagille Syndrome or those exhibiting symptoms related to the disease, as it can guide treatment decisions and inform about the risk of passing the condition to future generations.
